Key result
OAC prescribing in hospitalized AF climbs to ~97% by 2019.
Why the study?
Antithrombotic prophylaxis in patients with atrial fibrillation has changed significantly in recent years, necessitating assessment of temporal trends and factors influencing oral anticoagulant use.
Observational (n=9,656)
No
Absolute Event Rate: 97.4% vs 61.6%
Oral anticoagulant prescription in hospitalized patients with atrial fibrillation increased significantly from 61.6% in 2004 to 97.4% in 2019.
Supports rising OAC adoption in AF; leaves open outcome impact in real-world hospitalized cohorts.
BACKGROUND: In the recent years, antithrombotic prophylaxis in patients with atrial fibrillation (AF) has changed significantly. The main aim of this study is to assess the temporal trends of antithrombotic therapy and identify factors predisposing oral anticoagulant (OAC) use in stroke prevention in AF patients. METHODS: The present study is a retrospective, observational, single-center study, which includes consecutively hospitalized patients in the reference cardiology center from January 2004 to December 2019. RESULTS: A total of 9656 patients (43.7% female, mean age 71.2 years) with AF between 2004-2019 are included. Among the total study population, in most of the patients (81.1%), OAC therapy was used, antiplatelet (APT) therapy was prescribed for 13.5% patients, heparins for 2.1% patients and 3.3% of patients did not receive any stroke prevention. OAC prescription significantly increased from 61.6% in 2004 to 97.4% in 2019. The independent predictors of OAC prescription were: the period of hospitalization, non-paroxysmal AF, age, hypertension, diabetes mellitus, previous thromboembolism, hospitalization due to electrical cardioversion, ablation or AF without any procedures. CONCLUSIONS: -VASc score were independent predictors of OAC use.
No takes yet. Share an insight, caveat, or question.
Bielecka et al. (2022) conducted an observational in atrial fibrillation (n=9,656). Oral anticoagulant (OAC) prescription vs. Earlier time period (2004) was evaluated on OAC prescription rate. Oral anticoagulant prescription in hospitalized patients with atrial fibrillation significantly increased from 61.6% in 2004 to 97.4% in 2019.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: